Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene, under the aliases “HPYR1,” “LINC00027,” “HPRG1,” “NCRNA00027,” and “non-protein coding RNA 27,” is annotated as a *long non-coding RNA (lncRNA)* with no protein-coding capacity. There is no validated functional or therapeutic literature associating this lncRNA with canonical *Helicobacter pylori* response pathways, nor is it defined as a receptor, enzyme, transporter, or classic drug target. It is not listed in major pharmacological or therapeutic target compendia. Curation in public databases (such as NCBI Gene, Ensembl, and GENCODE) references its existence as a long intergenic non-coding RNA, but with largely **unknown biological function** and without strong evidence for disease relevance or targetability. **Assessment** - This “target” is not a validated therapeutic target or receptor; it is indexed as a non-coding RNA of currently undetermined function, with no evidence of relevance to *H. pylori* response in the context of current molecular medicine. - The submitted list conflates *Helicobacter pylori* itself (a bacterial pathogen) with an uncharacterized human gene annotation (“LINC00027”), which leads to confusion; the names are not well established in the biomedical literature. If you are seeking information on *Helicobacter pylori* pathogenesis, regulatory systems, or non-coding RNAs implicated in the bacterial response (such as pH-responsive transcriptional regulation in *H. pylori*[1] or small bacterial RNAs such as HPnc4160[2]), these are separate and well-defined topics unrelated to the above human gene symbol. The entry is therefore not a canonical or therapeutically actionable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 27 (LINC00027).